Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Inclusion Criteria: 1. Histological or cytological diagnosis of hepatocellular cancer; 2. At least one measurable lesion was assessed according to RECIST1.1 criteria. 3. Age from 18 to 75,ECOG physical strength score reaches 0-2; 4. After first-line targeted therapy, it was assessed as advanced or intolerant according to RECIST1.1 criteria. 5. Child-pugh grade A or B for liver function; 6. Bone marrow function was basically normal: neutrophils \> 1.5x 10\^9/L, platelets \> 75 x10\^9/L; 7. Adequate renal reserve: creatinine \<130 mol/L; 8. Centerless dysfunction, chest pain (medically uncontrollable), no myocardial infarction within 12 months prior to study initiation; 9. Estimated survival ≥3 months; 10. Signed the informed consent. Exclusion Criteria: 1. Previous application of PD-1 inhibitor and anlotinib; 2. Secondary malignant tumors or other tumors (except superficial skin cancer and localized low-grade malignant tumors) occurring within 3 years prior to the start of the study; 3. Metastasis of the brain or meninges; 4. Imaging findings indicated that the tumor was involved in important blood vessels or that the researchers had assessed that it might lead to fatal bleeding during follow-up; 5. Bleeding events at any site ≥CTCAE level 3 occurred 4 weeks before medication, and there were unhealed wounds, ulcers or fractures; 6. The time of occurrence of arteriovenous thrombosis, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within 6 months before enrollment; 7. Untreated intestinal obstruction or subobstruction that cannot eat or affect systemic administration; 8. Patients with active infection or other possible disorders receive inflammatory infections under planned management; 9. Have a history of uncontrolled substance abuse or mental disorders; 10. In the judgment of the investigator, patients with concomitant diseases that may seriously endanger their own safety or may affect the completion of the study; 11. Participated in other clinical trials; 12. Pregnant and nursing women;